CEL-SCI Corp shares tumble after drug trial update
28/06/2021 16:47
** Shares in CEL-SCI Corp CVM.A , an immunotherapy company
working on a treatment for head and neck cancer patients, down
43.7% at $14.13, on track for its biggest one-day pct decline
ever after its drug study did not meet its goals
** CEL-SCI announced that complete study population to which
the Multikine treatment regimen was administered was compared to
control, study did not achieve primary endpoint of 10%
improvement in overall survival urn:newsml:reuters.com:*:nBw4PpRnva
** The company said however that since a lower risk subgroup
the treatment exceeded the goal it plans to seek FDA approval
for this population
** After CVM rose to a high of $27.28 right after the market
open the stock soon sank to a low of $9 before regaining some
ground. Trading volume was 10.4 times 10-DMA
(Reporting By Sinéad Carew)
((sinead.carew@thomsonreuters.com; +1 (646) 223 6186; Reuters
Messaging: sinead.carew.thomsonreuters.com@reuters.net))